NuProbe’s Post

ESR1 mutation detection from liquid biopsy or FFPET– order your CE-IVD dPCR test from BIOTYPE!   🔬Exciting news: Orserdu (Elacestrant), the innovative anti-oestrogen, is now available in Germany after EMA approval in September. Patients are eligible for treatment with Orserdu if their cancer cells exhibit oestrogen receptors on their surface (ER-positive), lack significant quantities of the HER2 receptor (HER2-negative), and have a confirmed mutation in the ESR1 gene. For accurate ESR1 testing, liquid biopsy on blood is mandated. 🧬Blood-based ctDNA liquid biopsy or FFPET-DNA testing by digital PCR, in line with several medical guidelines in oncology, offers superior sensitivity in detecting ESR1 mutations. 🧪BIOTYPE will support the nationwide supply of ESR1 testing.   If you are interested in learning more about ESR1 testing, klick the link below or contact us for more information:   https://lnkd.in/eNQxvuYa #ESR1 #HER2 #liquidbiopsy #breastcancer #oncology

Predicting response to checkpoint inhibitor therapy is challenging. What if there was a way to identify individuals who would respond favorably to checkpoint inhibitor therapy based on biomarkers found in blood? Read our latest blog “Biomarker discovery leading the way in PD-L1 expression and PD-1 checkpoint inhibitor therapy” to learn more about complex cancer pathways and to investigate the potential of targeting PD-L1 expression & the PD-1 checkpoint pathway in cancer. https://lnkd.in/g6pffxEC #CancerResearch #Proteomics

Interested in targeting tumor metastasis? Therapeutic antibodies and ADCs targeting cadherins are a promising therapeutic strategy for treating metastatic cancer, most recently highlighted by Daiichi Sankyo's deal with MSD for CDH6. Classic cadherins are calcium-dependent transmembrane glycoproteins that play an important role in cell-cell adhesion. 🐁We're using our RenMice® to discover fully human antibodies targeting CDH3, CDH6, and CDH11, which will streamline clinical development.  Contact us for off-the-shelf cadherin antibodies: [email protected]. #CancerResearch #Cadherins #ADCs #cancertherapy #therapeutics

Predicting response to checkpoint inhibitor therapy is challenging. What if there was a way to identify individuals who would respond favorably to checkpoint inhibitor therapy based on biomarkers found in blood? Read our latest blog "Biomarker discovery leading the way in PD-L1 expression and PD-1 checkpoint inhibitor therapy" to learn more about complex cancer pathways and to investigate the potential of targeting PD-L1 expression & the PD-1 checkpoint pathway in cancer. https://lnkd.in/g6pffxEC #CancerResearch #Proteomics

Predicting response to checkpoint inhibitor therapy is challenging. What if there was a way to identify individuals who would respond favorably to checkpoint inhibitor therapy based on biomarkers found in blood? Read our latest blog "Biomarker discovery leading the way in PD-L1 expression and PD-1 checkpoint inhibitor therapy" to learn more about complex cancer pathways and to investigate the potential of targeting PD-L1 expression & the PD-1 checkpoint pathway in cancer. https://lnkd.in/g6pffxEC #CancerResearch #Proteomics

What an interesting webinar on HRD evaluation and scoring for ovarian cancer patients using the Oncoscan. HR, Homologous Recombination, is a pathway that repairs double stranded breaks in DNA and ultimatley preventing the accumulation of transforming mutations. Several genomic scars including loss of heterozygosity LOH, telomeric allelic imbalance TAI, large-scale state transitions LST were found to be associated with HRD. Including BRCA1/2 mutations. HRD, in the germaline context, can confer risk to ovarian, breast, prostate and other cancers. it also occurs somatically and can confer cancer development, currently ovarian, breast and prostate. HRD cells could be targeted with specific DNA damaging agents and/or synthetic lethal targeting approaches such as PARP inhibitors.

The G12C mutation is one of the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), and oncogenic RAS signaling has been shown to promote an immunosuppressive tumor microenvironment by upregulating PD-L1 expression. At SITC 2023, WuXi AppTec scientists presented a poster showing that combination therapy of the KRAS G12C inhibitor AMG 510 with the anti-PD-1 antibody nivolumab resulted in significant anti-tumor activity in preclinical humanized NSCLC mouse models. Click below to download our SITC poster! Questions? Contact us at [email protected] #biotech #biopharma #drugdiscovery #oncology #KRAS #PDL1 #PD1 #SITC #NSCLC #G12C #oncogenic

HETEROCYCLIC-CONTAINING HDAC INHIBITORS ACTIVE IN CANCER Cancer is a leading cause of mortality worldwide. A biological target validated in recent years in the pharmacological armamentarium are histone deacetylases (HDACs), epigenetic enzymes that remove acetyl groups from lysines present on histone tails, and overexpressed in various types of cancer. The first HDA inhibitor in history to be approved by the FDA (October 2006) was Zolinza (vorinostat), used to treat Cutaneous T-cell Lymphoma. To date, there are several HDA inhibitors approved by regulatory bodies: vorinostat (SAHA), romidepsin (FK-228), panobinostat (LBH589), and belinostat (PDX-101) are approved by the Food and Drug Administration. In 2021, China and Japan have approved the use of chidamide (epidaza/tucidinostat; HBI-8000), a new subtype-selective HDACi that inhibits class 1 HDAC1, HDAC2, HDAC3, as well as class 2b HDAC10. Many of these inhibitors are based on a heterocyclic structure, a structural element that has been particularly interesting in the design of this class of compounds. An updated review, just published in ChemMedChem, summarizes all major studies conducted so far on HDAC inhibitors, with heterocyclic rings, as their therapeutic potential is well known and has gained increasing interest in recent years. Therefore, the insertion of heterocyclic moieties into the scaffold that inhibits HDAC may be a valuable strategy to deliver potent and/or selective compounds. Here, in addition to summarizing the properties of new heterocyclic HDAC-inhibiting compounds, ideas are provided for the development of novel, more potent and selective compounds for the treatment of cancer. #heterocyclic #HDAC #cancer

They say good things come in threes so here's out third preprint of the month! In collaboration with the Witze lab in Cancer Biology, we developed the first selective small molecule inhibitors of a palmitoyl transferase! Our lead compound phenocopies genetic ablation of DHHC20, reducing EGFR palmitoylation, Akt phosphorylation and Myc expression. Excitingly it's also orally bioavailable and significantly improves survival in KRas mutant lung cancer xenografts. Finally, we were able to use our recently published proximity ligation imaging approach to demonstrate on-target activity in vivo! https://lnkd.in/ekQHXdqj https://lnkd.in/e235KXNt

Explore the synergistic effect of a KRAS inhibitor combined with ICI in an in vivo tumor model study. Check out this SITC 2023 poster for more details.